Pyrazolo (5,1-b) oxazole derivatives as CRF1 antagonists

Details for Australian Patent Application No. 2009279137 (hide)

Owner Novartis AG

Inventors Bruce, Ian; Culshaw, Andrew James; Devereux, Nicholas James; Gessier, Francois; McKenna, Jeffrey; Neef, James; Oakman, Helen Elizabeth

Agent Davies Collison Cave

Pub. Number AU-A-2009279137

PCT Pub. Number WO2010/015628

Priority 09150553.7 14.01.09 EP; 08161930.6 06.08.08 EP; 61/205,096 14.01.09 US

Filing date 4 August 2009

Wipo publication date 11 February 2010

International Classifications

C07D 498/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/424 (2006.01) - condensed with heterocyclic ring systems, e.g. clavulanic acid

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

17 February 2011 PCT application entered the National Phase

  PCT publication WO2010/015628 Priority application(s): WO2010/015628

3 March 2011 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Novartis AG, Application No. 2009279137, under INID (54) correct the title to Pyrazolo [5,1-b] oxazole derivatives as CRF1 antagonists

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009279142-Method for characterizing, in particular for quantifying, molecular markers that are intracellularly absorbed from tissues by blood macrophages that are recirculated from the tissues into the circulatory system

2009279135-Crystalline forms of a pyridine derivative